23/04/2010
Poor 'Less Likely' To Get Prostate Cancer Care
It has been reported in a study that men living in deprived areas are less likely to receive treatment for prostate cancer than their richer counterparts.
The British Medical Journal, researched 35,000 men and described their findings as "substantial" with regards to economic backgrounds.
However previous studies have suggested survival rates as high as 7% between the least and most deprived.
When cancer of the prostate is reported as low risk or localised, most men are regularly monitored, if further development is noticed doctors offer treatment such as surgery or radiotherapy.
Cambridge University noted that the use of surgery more than doubled between 1995 and 2006. However their study showed it was more likely to be taken up by the most affluent - with 8.4% of this group receiving treatment to remove the prostate gland compared with 4% of the worst-off patients.
Almost 29% of the wealthiest received radiotherapy, compared with 21% of the poorest.
This pattern continued even when age, stage of the disease and hospital were accounted for.
When considering patterns the authors noted a myriad of factors which include differences in the interactions between patient and doctor or the risks patients with varying educational backgrounds were prepared to take with their treatment.
Prostate cancer accounts for about 12% of male deaths from cancer in the UK and is the second most common cause of cancer death in men.
In older men aged 85 and over, the disease is the most common cause of all deaths from cancer.
(BMcN/BMcC)
The British Medical Journal, researched 35,000 men and described their findings as "substantial" with regards to economic backgrounds.
However previous studies have suggested survival rates as high as 7% between the least and most deprived.
When cancer of the prostate is reported as low risk or localised, most men are regularly monitored, if further development is noticed doctors offer treatment such as surgery or radiotherapy.
Cambridge University noted that the use of surgery more than doubled between 1995 and 2006. However their study showed it was more likely to be taken up by the most affluent - with 8.4% of this group receiving treatment to remove the prostate gland compared with 4% of the worst-off patients.
Almost 29% of the wealthiest received radiotherapy, compared with 21% of the poorest.
This pattern continued even when age, stage of the disease and hospital were accounted for.
When considering patterns the authors noted a myriad of factors which include differences in the interactions between patient and doctor or the risks patients with varying educational backgrounds were prepared to take with their treatment.
Prostate cancer accounts for about 12% of male deaths from cancer in the UK and is the second most common cause of cancer death in men.
In older men aged 85 and over, the disease is the most common cause of all deaths from cancer.
(BMcN/BMcC)
Related UK National News Stories
Click here for the latest headlines.
25 September 2009
Screening For Prostate Cancer 'Remains Controversial'
There is not enough evidence to support routine prostate cancer screening. Two papers published on bmj.com today conclude that there is insufficient evidence to support population-wide screening for prostate cancer using the prostate specific antigen (PSA) test.
Screening For Prostate Cancer 'Remains Controversial'
There is not enough evidence to support routine prostate cancer screening. Two papers published on bmj.com today conclude that there is insufficient evidence to support population-wide screening for prostate cancer using the prostate specific antigen (PSA) test.
24 May 2005
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
09 November 2004
Report highlights successful fight against prostate cancer
Men with prostate cancer are being seen more quickly and receiving better care according to a new report out today. The report sets out progress made following the publication of the NHS Prostate Cancer programme four years ago.
Report highlights successful fight against prostate cancer
Men with prostate cancer are being seen more quickly and receiving better care according to a new report out today. The report sets out progress made following the publication of the NHS Prostate Cancer programme four years ago.
31 October 2005
Call for action on prostate cancer
The leaders of the three main political parties have issued a joint call for greater action to tackle the problem of prostate cancer. Prime Minister Tony Blair, Conservative leader Michael Howard and Liberal Democrat leader Charles Kennedy have all recorded messages of support for the Prostate Cancer Charter for Action.
Call for action on prostate cancer
The leaders of the three main political parties have issued a joint call for greater action to tackle the problem of prostate cancer. Prime Minister Tony Blair, Conservative leader Michael Howard and Liberal Democrat leader Charles Kennedy have all recorded messages of support for the Prostate Cancer Charter for Action.
16 May 2012
New Info Revises Opinion On Cancer Drug
A prostate cancer drug should be given to NHS patients, a health watchdog has said. The National Institute for Health and Clinical Excellence (Nice) revised its recommendations on the drug Abiratone after fresh information from the manufacturer, Janssen. Experts have welcomed the draft guidance.
New Info Revises Opinion On Cancer Drug
A prostate cancer drug should be given to NHS patients, a health watchdog has said. The National Institute for Health and Clinical Excellence (Nice) revised its recommendations on the drug Abiratone after fresh information from the manufacturer, Janssen. Experts have welcomed the draft guidance.